Davit L Aghayan1, Airazat M Kazaryan2, Vegar Johansen Dagenborg3, Bård I Røsok4, Morten Wang Fagerland5, Gudrun Maria Waaler Bjørnelv6, Ronny Kristiansen7, Kjersti Flatmark3, Åsmund Avdem Fretland7, Bjørn Edwin8. 1. The Intervention Centre at Oslo University Hospital and Institute of Clinical Medicine at University of Oslo, Oslo, Norway, and Yerevan State Medical University after Mkhitar Heratsi, Yerevan, Armenia (D.L.A.). 2. The Intervention Centre at Oslo University Hospital, Oslo, and Østfold Hospital Trust, Grålum, Norway, Yerevan State Medical University after Mkhitar Heratsi, Yerevan, Armenia, and I.M. Sechenov First Moscow State Medical University, Moscow, Russia (A.M.K.). 3. Institute of Clinical Medicine at University of Oslo and Oslo University Hospital, Oslo, Norway (V.J.D., K.F.). 4. Oslo University Hospital Rikshospitalet, Oslo, Norway (B.I.R.). 5. Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway (M.W.F.). 6. Norwegian University of Science and Technology, Trondheim, Norway (G.M.W.). 7. The Intervention Centre at Oslo University Hospital, Oslo, Norway (R.K., Å.A.F.). 8. The Intervention Centre at Oslo University Hospital and Institute of Clinical Medicine at University of Oslo, Oslo, Norway (B.E.).
Abstract
BACKGROUND: Despite the recent worldwide dissemination of laparoscopic liver surgery, no high-level evidence supports the oncologic safety of this approach. OBJECTIVE: To evaluate long-term oncologic outcomes after laparoscopic versus open liver resection in patients with colorectal metastases. DESIGN: A single-center, assessor-blinded, randomized controlled trial (OSLO-COMET [Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Trial]). (ClinicalTrials.gov: NCT01516710). SETTING: Oslo University Hospital, the only provider of liver surgery for the 3 million inhabitants of southeastern Norway. PARTICIPANTS: Patients with resectable colorectal liver metastases were randomly assigned to have open or laparoscopic liver resection. INTERVENTION: From February 2012 to January 2016, a total of 280 patients were included in the trial (laparoscopic surgery: n = 133; open surgery: n = 147). MEASUREMENTS: The primary outcome was postoperative morbidity within 30 days. Five-year rates of overall and recurrence-free survival were predefined secondary end points. RESULTS: At a median follow-up of 70 months, rates of 5-year overall survival were 54% in the laparoscopic group and 55% in the open group (between-group difference, 0.5 percentage point [95% CI, -11.3 to 12.3 percentage points]; hazard ratio, 0.93 [CI, 0.67 to 1.30]; P = 0.67). Rates of 5-year recurrence-free survival were 30% in the laparoscopic group and 36% in the open group (between-group difference, 6.0 percentage points [CI, -6.7 to 18.7 percentage points]; hazard ratio, 1.09 [CI, 0.80 to 1.49]; P = 0.57). LIMITATION: The trial was not powered to detect differences in secondary end points and was not designed to address a noninferiority hypothesis for survival outcomes. CONCLUSION: In this randomized trial of laparoscopic and open liver surgery, no difference in survival outcomes was found between the treatment groups. However, differences in 5-year overall survival up to about 10 percentage points in either direction cannot be excluded. This trial should be followed by pragmatic multicenter trials and international registries. PRIMARY FUNDING SOURCE: The South-Eastern Norway Regional Health Authority.
BACKGROUND: Despite the recent worldwide dissemination of laparoscopic liver surgery, no high-level evidence supports the oncologic safety of this approach. OBJECTIVE: To evaluate long-term oncologic outcomes after laparoscopic versus open liver resection in patients with colorectal metastases. DESIGN: A single-center, assessor-blinded, randomized controlled trial (OSLO-COMET [Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Trial]). (ClinicalTrials.gov: NCT01516710). SETTING: Oslo University Hospital, the only provider of liver surgery for the 3 million inhabitants of southeastern Norway. PARTICIPANTS: Patients with resectable colorectal liver metastases were randomly assigned to have open or laparoscopic liver resection. INTERVENTION: From February 2012 to January 2016, a total of 280 patients were included in the trial (laparoscopic surgery: n = 133; open surgery: n = 147). MEASUREMENTS: The primary outcome was postoperative morbidity within 30 days. Five-year rates of overall and recurrence-free survival were predefined secondary end points. RESULTS: At a median follow-up of 70 months, rates of 5-year overall survival were 54% in the laparoscopic group and 55% in the open group (between-group difference, 0.5 percentage point [95% CI, -11.3 to 12.3 percentage points]; hazard ratio, 0.93 [CI, 0.67 to 1.30]; P = 0.67). Rates of 5-year recurrence-free survival were 30% in the laparoscopic group and 36% in the open group (between-group difference, 6.0 percentage points [CI, -6.7 to 18.7 percentage points]; hazard ratio, 1.09 [CI, 0.80 to 1.49]; P = 0.57). LIMITATION: The trial was not powered to detect differences in secondary end points and was not designed to address a noninferiority hypothesis for survival outcomes. CONCLUSION: In this randomized trial of laparoscopic and open liver surgery, no difference in survival outcomes was found between the treatment groups. However, differences in 5-year overall survival up to about 10 percentage points in either direction cannot be excluded. This trial should be followed by pragmatic multicenter trials and international registries. PRIMARY FUNDING SOURCE: The South-Eastern Norway Regional Health Authority.
Authors: Ahmad Ozair; Amelia Collings; Alexandra M Adams; Rebecca Dirks; Bradley S Kushner; Iswanto Sucandy; David Morrell; Ahmed M Abou-Setta; Timothy Vreeland; Jake Whiteside; Jordan M Cloyd; Mohammed T Ansari; Sean P Cleary; Eugene Ceppa; William Richardson; Adnan Alseidi; Ziad Awad; Subhashini Ayloo; Joseph F Buell; Georgios Orthopoulos; Samer Sbayi; Go Wakabayashi; Bethany J Slater; Aurora Pryor; D Rohan Jeyarajah Journal: Surg Endosc Date: 2022-09-22 Impact factor: 3.453
Authors: M D'Hondt; A Devooght; E Willems; D Wicherts; C De Meyere; I Parmentier; A Provoost; H Pottel; C Verslype Journal: J Robot Surg Date: 2022-03-24
Authors: Leonid Barkhatov; Davit L Aghayan; Vincenzo Scuderi; Federica Cipriani; Åsmund A Fretland; Airazat M Kazaryan; Francesca Ratti; Thomas Armstrong; Andrea Belli; Ibrahim Dagher; Giulio Belli; Luca Aldrighetti; Mohammad Abu Hilal; Roberto I Troisi; Bjørn Edwin Journal: Surg Endosc Date: 2021-08-30 Impact factor: 4.584
Authors: A A Burlaka; D E Makhmudov; I I Lisnyi; A V Paliichuk; V V Zvirych; A V Lukashenko Journal: World J Surg Oncol Date: 2022-04-17 Impact factor: 3.253
Authors: Andrew A Gumbs; Roland Croner; Eric Lorenz; Andrea Benedetti Cacciaguerra; Tzu-Jung Tsai; Lee Starker; Joe Flanagan; Ng Jing Yu; Elie Chouillard; Mohammad Abu Hilal Journal: Cancers (Basel) Date: 2022-08-29 Impact factor: 6.575
Authors: Moritz Schmelzle; Linda Feldbrügge; Santiago Andres Ortiz Galindo; Simon Moosburner; Anika Kästner; Felix Krenzien; Christian Benzing; Matthias Biebl; Robert Öllinger; Thomas Malinka; Wenzel Schöning; Johann Pratschke Journal: Surg Endosc Date: 2022-05-31 Impact factor: 3.453